CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Algernon Health Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Algernon Health Inc
Suite 400 - 601 West Broadway
Phone: (604) 398-4175p:604 398-4175 VANCOUVER, BC  V5Z 4C2  Canada Ticker: BTHCFBTHCF
Business Summary
Algernon Health Inc., formerly Algernon Pharmaceuticals Inc., is a Canadian healthcare company. The Company is focused on the provision of brain-specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer’s disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. It is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company also owns a 20% equity position in Seyltx, a private U.S-based drug development company advancing a chronic cough drug called Ifenprodil.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
5/31/20258/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
8093 Specialty outpatient facilities, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Michael T.Costanzo
President and Director KalMalhi
Lead Engineer RajAttariwala
Scientific Advisor Richard A.Yost

Business Names
Business Name
AGN
AGW
AGW0
6 additional Business Names available in full report.

General Information
Outstanding Shares: 34,256,219 (As of 6/3/2025)
Stock Exchange: CNQ
Fax Number: (604) 646-1553
Email Address: info@breathtecbiomedical.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, October 27, 2025